|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2006-2-20
|
|
pubmed:abstractText |
The accumulation of T cells into the tumor site is crucial for the elicitation of in vivo antitumor effects after cancer vaccination. In this study, we investigated the antitumor effects and associated mechanisms of action that were induced by systemic and local immunization with a CTL-directed peptide in combination with a peritumoral injection of a streptococcal preparation, OK-432.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1325-32
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16489090-Amino Acid Sequence,
pubmed-meshheading:16489090-Animals,
pubmed-meshheading:16489090-Antigens, Neoplasm,
pubmed-meshheading:16489090-Antineoplastic Agents,
pubmed-meshheading:16489090-CD4-Positive T-Lymphocytes,
pubmed-meshheading:16489090-CD8-Positive T-Lymphocytes,
pubmed-meshheading:16489090-Cancer Vaccines,
pubmed-meshheading:16489090-Cell Line, Tumor,
pubmed-meshheading:16489090-Combined Modality Therapy,
pubmed-meshheading:16489090-Flow Cytometry,
pubmed-meshheading:16489090-Immunoglobulin G,
pubmed-meshheading:16489090-Mice,
pubmed-meshheading:16489090-Mice, Inbred BALB C,
pubmed-meshheading:16489090-Neoplasms, Experimental,
pubmed-meshheading:16489090-Peptide Fragments,
pubmed-meshheading:16489090-Picibanil,
pubmed-meshheading:16489090-RNA-Binding Proteins,
pubmed-meshheading:16489090-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:16489090-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432.
|
|
pubmed:affiliation |
Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
